This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

J&J Completes Omrix Tender Offer

NEW BRUNSWICK, N.J. -- Johnson & Johnson (JNJ) said Saturday that it completed its tender offer for shares of Omrix Biopharmaceuticals Inc. (OMRI), a New York-based maker of liquid sealants used to control bleeding during surgery.

J&J said Omrix shareholders tendered about 97.8% of shares in response to a tender offer that expired at midnight Friday.

The $438 million buyout announced Nov. 24 is aimed at boosting the health-product company's surgical care business.

J&J said it intends to complete its acquisition without a vote or meeting of Omrix's remaining shareholders. Remaining shares will be converted into the right to receive $25 in cash each.

The company said it expects to close the deal as soon as possible. Omrix will then operate as a standalone entity connected to J&J's Ethicon surgical products unit.

Boards of directors of both companies have approved the deal, as has the Israeli government. Omrix's manufacturing operations are based in Tel Aviv.
Copyright 2008 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.05 -1.30%
FB $99.32 -1.70%
GOOG $674.41 -1.40%
TSLA $153.76 7.00%
YHOO $26.61 -1.80%


Chart of I:DJI
DOW 15,572.70 -342.04 -2.15%
S&P 500 1,822.68 -29.18 -1.58%
NASDAQ 4,233.4520 -50.14 -1.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs